Repligen Co. (NASDAQ:RGEN) Shares Sold by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company decreased its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 3.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 64,199 shares of the biotechnology company’s stock after selling 2,468 shares during the period. The Manufacturers Life Insurance Company owned approximately 0.11% of Repligen worth $9,241,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. UMB Bank n.a. grew its holdings in Repligen by 49.1% during the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock worth $48,000 after acquiring an additional 110 shares during the period. Oppenheimer & Co. Inc. acquired a new position in shares of Repligen during the 4th quarter worth $216,000. Van ECK Associates Corp increased its holdings in shares of Repligen by 7.8% in the 4th quarter. Van ECK Associates Corp now owns 42,226 shares of the biotechnology company’s stock valued at $6,078,000 after purchasing an additional 3,066 shares in the last quarter. Stephens Investment Management Group LLC lifted its stake in shares of Repligen by 7.4% in the fourth quarter. Stephens Investment Management Group LLC now owns 536,801 shares of the biotechnology company’s stock valued at $77,267,000 after purchasing an additional 37,057 shares during the period. Finally, Artemis Investment Management LLP lifted its stake in shares of Repligen by 18.4% in the fourth quarter. Artemis Investment Management LLP now owns 153,832 shares of the biotechnology company’s stock valued at $22,143,000 after purchasing an additional 23,905 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

RGEN has been the subject of a number of research reports. TD Cowen started coverage on shares of Repligen in a research report on Monday, February 10th. They set a “buy” rating and a $200.00 price target for the company. Evercore ISI initiated coverage on Repligen in a research report on Tuesday, March 18th. They set an “in-line” rating and a $155.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $180.00 price objective on shares of Repligen in a research report on Monday. JPMorgan Chase & Co. cut their target price on shares of Repligen from $200.00 to $190.00 and set an “overweight” rating for the company in a research report on Tuesday, April 29th. Finally, Canaccord Genuity Group dropped their price objective on shares of Repligen from $170.00 to $150.00 and set a “hold” rating for the company in a research note on Wednesday, April 16th. Six investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, Repligen currently has an average rating of “Moderate Buy” and a consensus price target of $173.25.

Insider Activity at Repligen

In other Repligen news, Director Margaret Pax bought 250 shares of Repligen stock in a transaction that occurred on Monday, March 17th. The shares were acquired at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the acquisition, the director now owns 1,043 shares of the company’s stock, valued at $157,169.67. The trade was a 31.53 % increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. 1.20% of the stock is currently owned by insiders.

Repligen Price Performance

Repligen stock opened at $140.92 on Tuesday. The company has a market cap of $7.91 billion, a price-to-earnings ratio of -276.31, a PEG ratio of 4.54 and a beta of 1.27. The firm has a 50 day moving average price of $137.38 and a 200 day moving average price of $145.84. Repligen Co. has a 1 year low of $102.97 and a 1 year high of $182.52. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, beating analysts’ consensus estimates of $0.35 by $0.04. The firm had revenue of $169.17 million for the quarter, compared to analysts’ expectations of $163.65 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The firm’s revenue for the quarter was up 10.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.28 earnings per share. Sell-side analysts predict that Repligen Co. will post 1.72 earnings per share for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.